Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 8 of 8 for “"Bisphosphonate treatment"”.
-
Association between Genetic Polymorphisms of Enzymes Involving Mevalonate Pathway(GGPS1 and FDPS) and Bone Mineral Density Response to Bisphosphonate Treatment
Geranylgeranyl diphosphate synthase1(GGPS1)과 farnesyl diphosphate synthase(FDPS)는 골다공증 치료제인 질소 함유 비스포스포네이트가 억제하는 표적효소로, 환자마다 비스포스포네이트에 대한 반응이 달리 나타나는 이유는 이 표적효소들의 유전자 다형성에서 기인하는 부분이 있을 것으로 생각된다. 본 연구의 목적은 GGPS1, FDPS 유전자에서 한국인 고유의 유전자 다형성을 찾고, 이에 따라 비스포스포네이트 투여에 대한 반응에 차이가 있는지를 평가하는 것이다. 골다공증 외에 …
-
Comparison of Pharmacologic Treatment on Bone Mineral Density in Patients with Osteopenia
… there are few studies about prevention and treatment of osteopenia and there is no consensus on the treatment of osteopenia. This study was carried out to compare effectiveness of bisphosphonates and calcium and vitamin D supplements on bone mineral density in patients with osteopenia. …
-
Modeling the Long Term Effects of Alendronate on Bone Mass Preservation of the Femur with Articular Surface and Total Hip Replacements
… Recently clinicians have been administering bisphosphonate drugs in an attempt to reduce the bone resorption due to stress shielding caused by these implants. Current strain-adaptive computational models with bisphosphonate treatment don’t predict the long term effects or look at treatment …
-
Alendronate treatment elicits a reduction in fatigue-life of canine cortical bone
… remodeling leads to osteoporotic fractures. Bisphosphonate drugs are proven to reduce fracture risk. However, the long-term effects of bisphosphonates on tissue-level properties are unknown. This study characterized the fatigue-life of cortical bone tissue after bisphosphonate treatment with …
-
Bone Mass Preservation and Fracture Risk Assessment with Bisphosphonate Therapy During Spaceflight
… success of the mission and postflight recovery. Bisphosphonates may be able to counteract this bone loss by altering the remodeling process. These drugs increase bone mass, thus reducing fracture risk, but also lead to increased levels of fatigue microdamage. Fracture risk can be lowered by …
-
Osteonecrosis of the jaw in association to bisphosphonates
The use of bisphosphonate has become more widespread for the treatment of bone metastasis, multiple myeloma, osteoporosis, Paget's disease and other bone malignancies. Osteonecrosis of the jaw (ONJ) has been recently recognized as a possible complication of the use of bisphosphonate therapy. This …
-
The clinical characteristics, complications and treatment outcomes of patients with osteoporosis at Groote Schuur Hospital
… between March 2019 and March 2020 for the treatment of osteoporosis. Patients folders were reviewed to obtain the following information: demographic data, risk factors, laboratory investigations, treatment, baseline and follow up DEXA scans. Results: 264 patients were evaluated, average age …
-
Understanding Hearing Loss in Osteogenesis Imperfecta
… No cure exists for OI or OI-hearing loss. While bisphosphonates remain the standard of care for OI, their effects on hearing are poorly understood. Treatments for OI-hearing loss are adapted from the general population but are often less effective. Despite the clinical burden, the mechanisms …